SCHEMBL22557746

SCHEMBL22557746

CC(=O)N1CCC(CSc2ccc(Br)c(F)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.39
DPP7 Q9UHL4 1/20 0.39
IDO1 P14902 1/20 0.39
RAB9A P51151 1/20 0.37
OPRL1 P41146 2/20 0.36
QDPR P09417 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
THRB P10828 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPK14 Q16539 1/20 0.35
IKBKB O14920 1/20 0.35
CHRM2 P08172 2/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30978719 1.00 DPP4 (0.39) DPP4DPP7IDO1RAB9AOPRL1
SCHEMBL22557714 0.84 IRAK4 (0.39) RAB9AQDPRTHRB
SCHEMBL30978716 0.84 IRAK4 (0.39) RAB9AQDPRTHRB
SCHEMBL22557666 0.83 AR (0.45) RAB9AQDPRCYP2C9CYP2C19
SCHEMBL22557673 0.82 ALDH1A1 (0.48) RAB9ATHRBMEN1KMT2A
SCHEMBL22585308 0.81 RAB9A (0.34) DPP4DPP7IDO1RAB9AQDPR
SCHEMBL22585192 0.81 AR (0.34) IDO1
SCHEMBL22585253 0.80 HDAC3 (0.44) DPP4DPP7OPRL1HDAC3HDAC1
SCHEMBL22585178 0.79 DPP4 (0.43) DPP4DPP7OPRL1HDAC3HDAC1
SCHEMBL22585179 0.78 HDAC3 (0.44) DPP4DPP7RAB9AOPRL1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162836-B2 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use Modern Biosciences Limited (GB) 2024-12-10 US disclosed
CN-113766953-B N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic uses 现代生物科学有限公司 2024-07-02 CN disclosed
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE ISTESSO THERAPEUTICS LIMITED (GB) 2023-01-26 US disclosed
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE ISTESSO THERAPEUTICS LIMITED (GB) 2023-01-26 US disclosed
EP-3956030-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE Modern Biosciences Limited (GB) 2022-02-23 EP disclosed
CN-113766953-A N-acyl- {4- [ (4-aryl-phenyl) sulfonylmethyl ] piperidine } compounds and their therapeutic use 现代生物科学有限公司 2021-12-07 CN disclosed
WO-2020212581-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE Modern Biosciences Limited (GB) 2020-10-22 WO disclosed
WO-2020212581-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE Modern Biosciences Limited (GB) 2020-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162836-B2 N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use MCL1, BCL9, BCL9L DPP4 1538/4885DPP7 2026/4885IDO1 693/4885
US-20230022917-A1 N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE MCL1, BCL9, BCL9L DPP4 1538/4885DPP7 2026/4885IDO1 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.